Study Evaluating Rapamune in Patients After Kidney Transplantation

N/ATerminatedNCT00240214

Wyeth is now a wholly owned subsidiary of Pfizer500 enrolled

Overview

The purpose of this study is to obtain data on the effectiveness and safety of Rapamune under everyday conditions

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Renal Transplantation

Interventions

sirolimusDRUG

Tablet, dosage is determined by trough level

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients having received a renal allograft from a cadaveric or living donor with low or moderate risk of developing acute rejection episodes. Exclusion Criteria: * Contraindications according to Summary of the Product Characteristics (SmPC).

Locations (1)

Unnamed facility

Multiple Cities, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.